$0.17
+0.00 (+0.82%)
Open$0.17
Previous Close$0.17
Day High$0.18
Day Low$0.17
52W High$20.60
52W Low—
Volume—
Avg Volume4.62M
Market Cap182.27M
P/E Ratio—
EPS$-5.94
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+6,390.7% upside
Current
$0.17
$0.17
Target
$11.19
$11.19
$8.32
$11.19 avg
$14.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.88M | 4.46M | 5.44M |
| Net Income | -169,945 | -168,167 | -171,039 |
| Profit Margin | -3.5% | -3.8% | -3.2% |
| EBITDA | -214,177 | -200,655 | -244,682 |
| Free Cash Flow | -155,731 | -123,018 | -136,236 |
| Rev Growth | -8.5% | +21.3% | +21.2% |
| Debt/Equity | 0.77 | 0.64 | 0.80 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |